Persistent Risk of Cardiac Structural Complications in TAVR: A Decade-Long Analysis Reveals High Mortality and Stagnant Incidence

Highlight

1. Cardiac structural complications (CSCs) occur in approximately 2.1% of contemporary TAVR procedures, a rate that has remained stable over the past decade.

2. Annular rupture is the most severe CSC, accounting for over 41% of structural compromise events and carrying the highest mortality risk.

3. Emergency conversion to open-heart surgery is required in 27.6% of patients experiencing a CSC, with nearly half of these patients dying within 30 days.

4. Despite improvements in valve design and operator experience, the incidence of these life-threatening events has not significantly decreased, suggesting a plateau in current procedural safety boundaries.

Background: The Evolution and Unresolved Risks of TAVR

Transcatheter aortic valve replacement (TAVR) has revolutionized the management of symptomatic severe aortic stenosis, expanding its reach from inoperable patients to those at low surgical risk. As the procedure becomes the standard of care across a broader demographic, the focus has shifted from demonstrating non-inferiority to surgery toward refining procedural safety and long-term durability. However, the inherent nature of TAVR—deploying a rigid prosthetic frame within a fragile, often calcified native anatomy—carries the risk of catastrophic physical injury to the heart.

Recently, the Valve Academic Research Consortium 3 (VARC-3) established a standardized definition for Cardiac Structural Complications (CSCs). These include life-threatening events such as cardiac structure perforation, injury, or compromise, new pericardial effusion, and coronary obstruction. While individual complications like annular rupture or coronary occlusion have been studied, there is a paucity of large-scale, contemporary data on the collective incidence and long-term trends of these events. Understanding whether technical advancements have successfully mitigated these risks is vital for informed consent and procedural planning.

Study Design and Methodology

To address this gap, a major multicenter study was conducted involving 18 high-volume centers across Europe and Canada. The study included a consecutive cohort of 10,541 patients who underwent TAVR between 2014 and 2024. This timeframe is particularly relevant as it captures the transition from early-generation devices to contemporary platforms (such as the SAPIEN 3 and Evolut PRO/FX).

The primary objective was to assess the incidence, timing, management, and clinical impact of CSCs as defined by VARC-3. Researchers utilized a dedicated database to track outcomes at 30 days, one year, and annually thereafter. CSCs were categorized into three main groups:

1. Cardiac Structure Compromise

Including annular rupture, left ventricular (LV) perforation, and right ventricular (RV) perforation (often related to temporary pacing leads).

2. New Pericardial Effusion

Defined as a new or worsening effusion, often requiring drainage or resulting in tamponade.

3. Coronary Obstruction

Partial or complete occlusion of the coronary ostia by native valve leaflets or the prosthetic frame.

Key Findings: A Persistent 2% Risk

The study revealed that CSCs occurred in 221 patients, representing an overall incidence of 2.1%. Interestingly, 1.2% of the total cohort (more than half of those with a CSC) exhibited more than one type of complication simultaneously, underscoring the catastrophic nature of these events.

Distribution of Complications

The 221 patients experienced a total of 355 individual events, categorized as follows:

– Cardiac Structure Compromise: 146 events (1.4% of total cohort). Within this group, annular rupture was the most frequent (41.1%), followed by LV perforation (26.0%) and RV perforation (24.0%).

– New Pericardial Effusion: 150 events (1.4% of total cohort).

– Coronary Obstruction: 59 events (0.6% of total cohort).

Timing and Management

The majority of CSCs (75.6%) were identified intraprocedurally, allowing for immediate intervention. However, the management of these events often required highly invasive measures. Emergency conversion to open-heart surgery was necessary for 61 patients (27.6% of those with a CSC). Other management strategies included pericardiocentesis, covered stent deployment for coronary obstructions, or conservative management in less severe cases of effusion.

The Mortality Burden

The clinical impact of CSCs was severe. The 30-day mortality rate for patients experiencing any CSC was 35.3%. This risk was even higher for specific subgroups:

– Patients requiring conversion to surgery: 47.5% mortality.

– Patients with annular rupture: 41.0% mortality.

Even among survivors, the occurrence of a CSC was associated with a significantly higher risk of long-term mortality compared to those who had an uncomplicated procedure.

Analysis of 10-Year Trends

One of the most striking findings of the study was the stability of the CSC incidence rate over time. Despite a decade of progress in pre-procedural CT planning, smaller delivery systems, and enhanced operator proficiency, the annual rate of CSCs fluctuated between 1.3% and 3.2%, with a median annual rate of 2.3%. There was no statistically significant downward trend observed between 2014 and 2024. This suggests that while we have improved at treating more complex patients, the baseline mechanical risks of the TAVR procedure remain a constant reality.

Expert Commentary: Why Isn’t the Rate Dropping?

The lack of a decrease in CSC incidence is a point of concern for the interventional community. Several factors may contribute to this plateau. First, as TAVR technology has improved, clinicians have pushed the boundaries to include more complex anatomical cases, such as bicuspid aortic valves, severely calcified LV outflow tracts (LVOT), and patients with low-lying coronary arteries. The increased complexity of the patient population likely offsets the gains made in device technology.

Furthermore, annular rupture remains highly correlated with aggressive balloon pre-dilation or the use of oversized balloon-expandable valves in the presence of heavy LVOT calcification. While CT-based sizing has become standard, the inherent limits of tissue elasticity cannot always be predicted by imaging alone.

The high mortality rate associated with surgical conversion—nearly 50%—also raises questions about the optimal bailout strategy. In some instances, the time required to initiate cardiopulmonary bypass in a catheterization lab setting may be too long to prevent irreversible organ damage or death. This highlights the need for a highly coordinated ‘Heart Team’ response and perhaps a more selective approach to surgical intervention in the most moribund patients.

Conclusion and Clinical Implications

The study by Mas-Peiro and colleagues provides a sobering look at the current state of TAVR safety. While a 2.1% complication rate might seem low, the associated 35% mortality rate makes CSCs one of the most significant remaining hurdles in transcatheter heart valve therapy.

Moving forward, the focus must shift toward prevention. This includes more sophisticated AI-driven CT analysis to identify ‘high-risk’ calcification patterns and the potential development of more conformable valve frames that exert less radial force on the annulus. Additionally, for centers performing TAVR, maintaining a high level of surgical readiness is essential, even if the need for conversion is rare. Future research should prioritize identifying the specific anatomical and procedural predictors of these complications to refine patient selection and procedural strategy.

References

1. Mas-Peiro S, Muntané-Carol G, Ternacle J, et al. Cardiac Structural Complications Following TAVR. Circ Cardiovasc Interv. 2026 Feb 5:e015991. doi: 10.1161/CIRCINTERVENTIONS.125.015991.

2. VARC-3 Writing Committee. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021;77(21):2717-2746.

3. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705.